336 related articles for article (PubMed ID: 36780428)
21. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
22. Generation of CAR-T cells using lentiviral vectors.
Poorebrahim M; Quiros-Fernandez I; Fakhr E; Cid-Arregui A
Methods Cell Biol; 2022; 167():39-69. PubMed ID: 35152998
[TBL] [Abstract][Full Text] [Related]
23. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
[TBL] [Abstract][Full Text] [Related]
24. A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia.
Weng J; Lai P; Qin L; Lai Y; Jiang Z; Luo C; Huang X; Wu S; Shao D; Deng C; Huang L; Lu Z; Zhou M; Zeng L; Chen D; Wang Y; Chen X; Geng S; Robert W; Tang Z; He C; Li P; Du X
J Hematol Oncol; 2018 Feb; 11(1):25. PubMed ID: 29458388
[TBL] [Abstract][Full Text] [Related]
25. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
[TBL] [Abstract][Full Text] [Related]
26. Treatment of advanced leukemia in mice with mRNA engineered T cells.
Barrett DM; Zhao Y; Liu X; Jiang S; Carpenito C; Kalos M; Carroll RG; June CH; Grupp SA
Hum Gene Ther; 2011 Dec; 22(12):1575-86. PubMed ID: 21838572
[TBL] [Abstract][Full Text] [Related]
27. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
[TBL] [Abstract][Full Text] [Related]
29. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
Kochenderfer JN; Dudley ME; Feldman SA; Wilson WH; Spaner DE; Maric I; Stetler-Stevenson M; Phan GQ; Hughes MS; Sherry RM; Yang JC; Kammula US; Devillier L; Carpenter R; Nathan DA; Morgan RA; Laurencot C; Rosenberg SA
Blood; 2012 Mar; 119(12):2709-20. PubMed ID: 22160384
[TBL] [Abstract][Full Text] [Related]
30. Production and characterization of haploidentical CD19 CAR T cells: Validated to induce a continuous complete remission in a patient with relapsed refractory B-cell ALL.
Prasongtanakij S; Anurathapan U; Vanichapol T; Jittorntrum B; Atjanasuppat K; Pongpitcha P; Pakakasama S; Songdej D; Sirachainan N; Paisooksantivatana K; Borwaornpinyo S; Andersson BS; Hongeng S
Asia Pac J Clin Oncol; 2022 Feb; 18(1):44-51. PubMed ID: 32970928
[TBL] [Abstract][Full Text] [Related]
31. Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients.
Itzhaki O; Jacoby E; Nissani A; Levi M; Nagler A; Kubi A; Brezinger K; Brayer H; Zeltzer LA; Rozenbaum M; Vernitsky H; Markel G; Toren A; Avigdor A; Schachter J; Besser MJ
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32152221
[TBL] [Abstract][Full Text] [Related]
32. Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering.
Michels KR; Sheih A; Hernandez SA; Brandes AH; Parrilla D; Irwin B; Perez AM; Ting HA; Nicolai CJ; Gervascio T; Shin S; Pankau MD; Muhonen M; Freeman J; Gould S; Getto R; Larson RP; Ryu BY; Scharenberg AM; Sullivan AM; Green S
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918221
[TBL] [Abstract][Full Text] [Related]
33. Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol.
Tang XY; Sun Y; Zhang A; Hu GL; Cao W; Wang DH; Zhang B; Chen H
BMJ Open; 2016 Dec; 6(12):e013904. PubMed ID: 28039295
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy.
Li W; Ding L; Shi W; Wan X; Yang X; Yang J; Wang T; Song L; Wang X; Ma Y; Luo C; Tang J; Gu L; Chen J; Lu J; Tang Y; Li B
J Transl Med; 2023 Mar; 21(1):213. PubMed ID: 36949487
[TBL] [Abstract][Full Text] [Related]
35. Genetic Mechanism of Leukemia Relapse Following CD19 Chimeric Antigen Receptor T Cell Therapy.
Qiu S; Pan Y; Shi S; Omotoyosi FF; Chen K; Guo Z; Lü P
Cancer Biother Radiopharm; 2022 Jun; 37(5):335-341. PubMed ID: 33739864
[TBL] [Abstract][Full Text] [Related]
36. CD19 CAR Therapy for Acute Lymphoblastic Leukemia.
Sadelain M; Brentjens R; Rivière I; Park J
Am Soc Clin Oncol Educ Book; 2015; ():e360-3. PubMed ID: 25993197
[TBL] [Abstract][Full Text] [Related]
37. Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia.
Magnani CF; Mezzanotte C; Cappuzzello C; Bardini M; Tettamanti S; Fazio G; Cooper LJN; Dastoli G; Cazzaniga G; Biondi A; Biagi E
Hum Gene Ther; 2018 May; 29(5):602-613. PubMed ID: 29641322
[TBL] [Abstract][Full Text] [Related]
38. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.
Kochenderfer JN; Rosenberg SA
Nat Rev Clin Oncol; 2013 May; 10(5):267-76. PubMed ID: 23546520
[TBL] [Abstract][Full Text] [Related]
39. Optimization of canine CD20 chimeric antigen receptor T cell manufacturing and in vitro cytotoxic activity against B-cell lymphoma.
Sakai O; Igase M; Mizuno T
Vet Comp Oncol; 2020 Dec; 18(4):739-752. PubMed ID: 32329214
[TBL] [Abstract][Full Text] [Related]
40. CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models.
Tsukahara T; Ohmine K; Yamamoto C; Uchibori R; Ido H; Teruya T; Urabe M; Mizukami H; Kume A; Nakamura M; Mineno J; Takesako K; Riviere I; Sadelain M; Brentjens R; Ozawa K
Biochem Biophys Res Commun; 2013 Aug; 438(1):84-9. PubMed ID: 23872144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]